ISRCTN15253766 https://doi.org/10.1186/ISRCTN15253766

Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina

Submission date 21/02/2006	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 29/03/2006	**Overall study status** Completed	
Last Edited 08/11/2011	**Condition category** Circulatory System	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Narasimharajapura Rajendra

Contact details
Dept of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY
+44 (0)1382 496355

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
JUS002

Study information

Scientific Title

Study objectives
Xanthine oxidase inhibition in chronic stable angina improves endothelial function.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved by the Regional Ethics Committee on 08/11/2005, reference number: 05/S1401/101

Study design
Randomised double blind placebo-controlled crossover trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Chronic stable angina

Interventions
Allopurinol versus placebo

Intervention Type
Drug

Phase
Not Specified

Drug/device/biological/vaccine name(s)
Allopurinol

Primary outcome measure
Change in endothelial function as assessed by:
1. Flow-mediated dilatation
2. Forearm venous occlusion plethysmography

Secondary outcome measures
Changes in brain natriuretic peptide (BNP)

Overall study start date
05/01/2006

Completion date
02/04/2008

Eligibility

Key inclusion criteria
1. Documented coronary artery disease
2. Chronic stable angina

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
88

Key exclusion criteria
1. Left ventricular systolic dysfunction
2. Renal failure
3. Concomitant warfarin therapy
4. Allergy to allopurinol

Date of first enrolment
05/01/2006

Date of final enrolment
02/04/2008

Locations

Countries of recruitment
Scotland

United Kingdom

Study participating centre

Dept of Clinical Pharmacology
Dundee
United Kingdom
DD1 9SY

Sponsor information

Organisation
University of Dundee (UK)

Sponsor details
The Nethergate
University of Dundee
Dundee
Scotland
United Kingdom
DD1 4HN

Sponsor type
University/education

ROR
https://ror.org/03h2bxq36

Funder(s)

Funder type
Charity

Funder Name
The British Heart Foundation (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	16/08/2011		Yes	No